Tülin FIRAT, Melahat DÖNMEZ, Aysel KÜKNER, Bülent DURAN, Önder KOÇ, Ata TOPÇUOĞLU

Gebelikte erdostein kullanımının sıçan fetus akciğer matürasyonu zzerine olan etkileri

Amaç: Bu çalışma 2 ve 4 mg erdostein kullanımının fetusların akciğer olgunlaşması üzerine olası etkilerinin araştırılması için planlandı. Gereç ve Yöntem: Wistar albino cinsi gebe sıçanlar: grup I (n=10): SHAM; grup II (n=10): 2 mg erdostein, grup III (n=10): 4 mg erdostein olarak 3 gruba ayrıldı. Gebe sıçanlara gebeliğin birinci haftası sonunda ilaç uygulaması başlandı ve sıçan fetuslarının 13. ve 18. günlerde laparotomi ile alındığı günün öncesine kadar devam edildi. Laparotomiyi takiben batın dışına alınan fetusların fetal doğum ağırlıkları, baş-makat uzunlukları, tüm akciğer ağırlıkları ölçüldü. Histopatolojik olarak akciğer matürasyonu değerlendirildi. Fetuslar akciğer gelişim evrelerine göre gruplandırıldı. Bulgular: Grup I , II ve III arasında 13 günlük fetuslarda doğum kilosu, baş-makat uzunluğu açısından anlamlı fark yoktu. Sadece akciğer ağırlığı açısından grup III değerleri grup I’ e göre anlamlı olarak yüksekti (p

Effects of erdostein use in pregnancy on fetal rat lung maturation

Objective: This study was planned for investigating the probable effects of 2 and 4 mg erdostein use on fetal lung maturation Materials and Methods: Wistar-Albino pregnant rats were divided into 3 groups as group I (n=10): SHAM; group II (n=10): Erdosteine 2mg, group III (n=10):Erdosteine 4 mg. The medication were given orally to pregnant rats at the end of first week and continued until the day of fetus excision by laparotomy at day 13 or day 18. Following the delivery, birth weight, crown-rump length, weight of whole lung were measured. The maturation of lungs were evaluated histopathologically. Fetuses were grouped according to the developmental stages of lungs. Results : There were no significant differences in birth weight and crown-rump length between the group I, II and III for the fetuses of day 13. Only whole lung weights of group III was significantly higher compared to group I (p

PDF

___

1. Lorenz JM, Wooliever DE, Jetton JR, Paneth N. A quantitative review of mortality and developmental disability in extremely premature newborns. Arch Pediatr Adolesc Med 998; 152: 425- 35.
2. Speer CP. Neonatal respiratory distress syndrome: an inflammatory disease? Neonatology 2011; 99(4): 316-9.
3. Engin-Üstün Y, Kafkaslı A, Boz M, Karadağ N, Gebe rat fetuslarında tek ve tekrarlanan doz kortikosteroid kullanımının organ maturasyonu ve beyin gelişimi üzerine olan etkilerinin değerlendirilmesi. Perinatoloji Dergisi 2006; 14(2): 59-62.
4. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. J Am Med Assoc 1995; 273: 413-18.
5. Uno H, Lohmiller L, Thieme C, et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I: hippocampus. Dev Brain Res 1990; 53: 157-67.
6. Quinlivan JA, Archer MA, Dunlop SA, Evans SF, Beazley LD, Newnham JP. Fetal growth retardation, particularly within lymphoid organs, following repeated maternal injections of betamethasone in sheep. J Obstet Gynecol Res 1998; 24: 173-82.
7. French NP, Evans SF, Godfrey KF, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999; 180: 114-121.
8. Laoag-Fernandez JB, Fernandez AM, Maruo T. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. J Obstet Gynaecol Res 2000; 26(4): 307-12.
9. Rayburn WF, Zuspan FP. Drug Therapy in Obstetrics and Gynecology. Third edition. Mosby Year book, Inc 1992. 90-102.
10. Dechant KL and Noble S. Erdosteine. Drugs 1996; 52: 875-881.
11. Braga PC, Dal Sasso M. Zuccotti T. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung 2000; 50: 739-746.
12. Bolser DC. Evidence-based clinical practice guidelines:cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 238- 249.
13. Dal Negro RW. Erdosteine: antitussive and anti-inflammatory effects. Lung. 2008; 186 Suppl 1:S70-3.
14. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2007 Dec 1(3):307-16.
15. Yamada T, Suzuki E, Gejyo F, Ushiki T. Developmental changes in the structure of the rat fetal lung with special reference to the airway smooth muscle and vasculature. Arch Histol Cytol 2002; 65: 55-69.
16. Burri PH. Fetal and postnatal development of the lung. Annu Rev Physiol 1984; 46:617-628.
17. Weng T, Chen Z, Jin N, Gao L, Liu L. Gene expression profiling identifies regulatory pathways involved in the late stage of rat fetal lung development. Am J Physiol Lung Cell Mol Physiol 2006; 291: L1027-37.
18. Demiralay R, Gürsan N, Erdem H. The effects of erdosteine, Nacetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells. Toxicology 2006; 15: 219(1-3): 197-207.
19. Yamada M, Kurihara H, Kinoshita K, Sakai T. Temporal expression of alpha-smooth muscle actin and drebrin in septal interstitial cells during alveolar maturation. J Histochem Cytochem 2005; 53: 735-44.
20. Lohninger AK, Böck P, Salzer H, Sevelda P, Lohninger AF. Antenatal betamethasone-dose-effects on fetal rat lung morphology and surfactant. J Perinat Med 1994; 22(4): 319-28.
21. Smolders-de Haas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. Pediatrics 1990; 86: 65.
22. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173: 254.
23. Sledziewski A, Kinalski M, Kretowski A. Analysis of selected methods for intrauterine stimulation of fetal pulmonary maturation. Przegl Lek 2000; 57(3): 171-7.
24. Newnham JP, Jobe AH. be prescribing repeated courses of antenatal corticosteroids? Semin Fetal Neonatal Med. Should we 2009; 14(3): 157-63.